Status:
COMPLETED
Bioequivalence Study of Zolpidem 10mg Tablets Under Fasting Conditions
Lead Sponsor:
Ranbaxy Laboratories Limited
Conditions:
Healthy
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The study compared the relative bioavailability (rate and extent of absorption) of 10 mg Zolpidem tablets by Ohm Laboratories Inc. with that of 10 mg Ambien® tablets distributed by Sanofi-Synthelabo, ...
Detailed Description
This was a single-center, randomized, open label, two-way cross over study conducted under fasting conditions. Subjects checked into the clinical facility the day prior to dosing at least 10 hours pri...
Eligibility Criteria
Inclusion
- Healthy men or women 18 years of age or older at the time of dosing
- Weights within ±20% for height and body frame as per Desirable weight for adults(1983 Metropolitan Height and Weight table)
- Volunteers judged by the investigator to be healthy based on their medical and medication history, physical examination, electrocardiogram, and clinical laboratory results
- Vounteers willing to participate in the study and have signed a copy of written consent form
- If female:
- Of childbearing potential, was practicing an acceptable method of birth control for the duration of study as judged by the investigator(s), such as condom with spermicide, intrauterine device (IUD), or abstinence; or Was menopausal for at least 1year; or Was surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy)
Exclusion
- Subject candidates must not be enrolled in the study if they meet any of the following criteria:
- Volunteers with a recent history of drug or alcohol addiction or abuse
- Volunteers with the presence of clinically significant disorder involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine, or neurologic system(s) or psychiatric disease (as determined by the clinical investigators)
- Volunteers with clinical laboratory test values outside the accepted reference range and, when confirmed on re-examination, were deemed to by clinically significant
- Volunteers with a reactive screen for hepatitis B surface antigen, hepatitis C antibody, or HIV antibody
- Volunteers with positive drug abuse screen when screened for the study
- Female volunteers demonstrating a positive pregnancy screen
- Female volunteers who are currently bre ast feeding
- Volunteers with a history of clinically significant allergies including the allergies
- Volunteers with any clinically significant illness during the 4 weeks prior to Period I dosing (as determined by the clinical investigation)
- Volunteers who currently use tobacco products
- Volunteers who had taken any drug known to induce metabolism or inhibit hepatic metabolism in the 28 days prior to the period I dosing.
- Volunteers who reported donating greater than 150 mL of blood within 28 days prior to period I dosing. All subjects were advised not to donate plasma for four weeks after completing the study
- Volunteers who had donated plasma (e.g. plasmapheresis) within 14 days prior to period I dosing. All subjects were advised not to donate plasma for four weeks after completing o the study
- Volunteers who reported receiving any investigational drug within 28 days prior to period I dosing
- Volunteers who reported taking any systemic prescription 14 days prior to Period I dosing
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2005
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00779051
Start Date
August 1 2005
End Date
October 1 2005
Last Update
October 24 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
PRACS Institute Ltd.
Fargo, North Dakota, United States, 58104